Sigilon Therapeutics, Inc. (SGTX)
Chart Events
Performance Outlook
| Previous Close | 0.6655 |
| Open | 0.6747 |
| Bid | 0.6667 x 2900 |
| Ask | 0.6900 x 1000 |
| Day's Range | 0.6580 - 0.7000 |
| 52 Week Range | 0.2900 - 2.0800 |
| Volume | |
| Avg. Volume | 251,063 |
| Market Cap | 21.754M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7600 |
| Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.95 |
- Simply Wall St.
Sigilon Therapeutics Third Quarter 2022 Earnings: Beats Expectations
Sigilon Therapeutics ( NASDAQ:SGTX ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.25m (up 118% from...
- Zacks
Sigilon Therapeutics, Inc. (SGTX) Reports Q3 Loss, Tops Revenue Estimates
Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 37.21% and 73.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated IND-enabling studies in 2023 Continued optimization of the MPS-1 program, with plans to initiate IND-enabling studies in the second half of 2023 CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop fu
